Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2016 07:00 ET | Source: ObsEva SA

ObsEva to Present at 2016 Wedbush Pacgrow Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva to Present at...
July 28, 2016 07:00 ET | Source: ObsEva SA

ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva Initiates Phase...
July 06, 2016 07:00 ET | Source: ObsEva SA

ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE ObsEva Receives Clearance...
April 05, 2016 08:00 ET | Source: ObsEva SA

ObsEva to Webcast Presentation at 15th Annual Needham Healthcare Conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 05 April, 2016 -...
March 24, 2016 08:08 ET | Source: ObsEva SA

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

GENEVA, March 24, 2016 (GLOBE NEWSWIRE) -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank...
March 24, 2016 08:00 ET | Source: ObsEva SA

ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 24 March 2016 - ObsEva, a...
November 23, 2015 05:00 ET | Source: ObsEva SA

ObsEva boucle un financement de Série B pour CHF 60 millions (USD 60 millions)

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Genève, Suisse, 23 novembre 2015 -...
November 23, 2015 05:00 ET | Source: ObsEva SA

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 23 November 2015 -...
November 20, 2015 01:06 ET | Source: ObsEva SA

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis

GENEVA, Switzerland, Nov. 20, 2015 (GLOBE NEWSWIRE) -- ObsEva and Kissei Pharmaceutical Co., Ltd. ("Kissei") today announced that they have entered into a collaboration agreement to develop and...
November 20, 2015 01:00 ET | Source: ObsEva SA

ObsEva et Kissei Pharmaceutical annoncent la signature d'un accord mondial pour le développement et la commercialisation du KLH-2109 pour le traitement de l'endométriose

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Genève, Suisse, 20 novembre 2015 -...